Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $4.0 million.

  • Altimmune's Change in Account Payables rose 35421.22% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 29189.75%. This contributed to the annual value of -$1.9 million for FY2024, which is 3200.44% up from last year.
  • Latest data reveals that Altimmune reported Change in Account Payables of $4.0 million as of Q3 2025, which was up 35421.22% from -$226000.0 recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Change in Account Payables peaked at $4.0 million during Q3 2025, and registered a low of -$1.6 million during Q3 2024.
  • For the 5-year period, Altimmune's Change in Account Payables averaged around $220631.6, with its median value being -$194000.0 (2021).
  • Examining YoY changes over the last 5 years, Altimmune's Change in Account Payables showed a top increase of 87229.78% in 2021 and a maximum decrease of 30818.99% in 2021.
  • Quarter analysis of 5 years shows Altimmune's Change in Account Payables stood at $2.0 million in 2021, then skyrocketed by 66.91% to $3.4 million in 2022, then crashed by 128.83% to -$976000.0 in 2023, then increased by 5.53% to -$922000.0 in 2024, then skyrocketed by 528.74% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, -$226000.0 for Q2 2025, and $866000.0 during Q1 2025.